Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039688 · ClinicalTrials.gov registry record · Phase 3
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 956
- Enrollment target
NCT01039688 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 956 participants.
The verdict
NCT01039688, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 956 participants
- Enrollment target
Study Summary
This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.
Interventions
- DRUG CP-690,550
- DRUG Disease-modifying antirheumatic drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 956 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039688
The ClinicalTrials.gov registry entry for NCT01039688 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 956 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-690,550 is the first listed.
NCT01039688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039688 about?
NCT01039688 is a clinical study titled "Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX". This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.
What is the current status of trial NCT01039688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 956 participants. The study started on 2010-01. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01039688?
The interventions under investigation include: CP-690,550 (DRUG), Disease-modifying antirheumatic drug (DRUG).
Who is sponsoring clinical trial NCT01039688?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.